アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

novel laboratories, inc. - zolpidem tartrate (unii: wy6w63843k) (zolpidem - unii:7k383oqi23) - zolpidem tartrate 1.75 mg - zolpidem tartrate sublingual tablet is indicated for use as needed for the treatment of insomnia when a middle-of-the-night awakening is followed by difficulty returning to sleep. limitations of use : zolpidem tartrate sublingual tablet is not indicated for the treatment of middle-of-the-night insomnia when the patient has fewer than 4 hours of bedtime remaining before the planned time of waking. zolpidem tartrate sublingual tablets are contraindicated in patients with known hypersensitivity to zolpidem. observed reactions with zolpidem include anaphylaxis and angioedema [see warnings and precautions (5.3)]. pregnancy category c there are no adequate and well-controlled studies of zolpidem in pregnant women. studies in children to assess the effects of prenatal exposure to zolpidem have not been conducted; however, cases of severe neonatal respiratory depression have been reported when zolpidem was used at the end of pregnancy, especially when taken with other cns-depressants. children born to mothers taking

アメリカ合衆国 - 英語 - NLM (National Library of Medicine)

novel laboratories, inc. - sodium phosphate, monobasic, monohydrate (unii: 593yog76rn) (sodium cation - unii:lyr4m0nh37), sodium phosphate, dibasic anhydrous (unii: 22ado53m6f) (sodium cation - unii:lyr4m0nh37) - sodium phosphate, monobasic, monohydrate 1.105 g - monobasic sodium phosphate and dibasic sodium phosphate tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in patients with biopsy-proven acute phosphate nephropathy. monobasic sodium phosphate and dibasic sodium phosphate tablets are contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. laxatives and purgatives (including monobasic sodium phosphate and dibasic sodium phosphate tablets) have the potential for abuse by bulimia nervosa patients who frequently have binge eating and vomiting.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: hyprolose; povidone; propylene glycol; purified talc; sodium starch glycollate type a; hypromellose; sodium starch glycollate type b; maize starch; magnesium stearate; colloidal anhydrous silica; poloxamer; glucose; titanium dioxide - adults: roxithromycin is indicated for the treatment of the following types of mild to moderately severe infections caused by or likely to be caused by susceptible microorganisms: upper respiratory tract infection: acute pharyngitis, tonsillitis and sinusitis. lower respiratory tract infection: acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia. skin and skin structure infections. nongonococcal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organism susceptibility and thus treatment suitability. therapy with roxithromycin may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - efavirenz, quantity: 200 mg - tablet, film coated - excipient ingredients: carnauba wax; hyprolose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; sodium lauryl sulfate; lactose monohydrate; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - stocrin is indicated for use in combination with other antiviral agents for the treatment of hiv-1 infection in adults and children (see clinical trials; use in children).

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 50 mg - tablet, dispersible - excipient ingredients: sodium lauryl sulfate; purified talc; fumaric acid; crospovidone; microcrystalline cellulose; methacrylic acid copolymer; colloidal anhydrous silica; triethyl citrate; macrogol 6000; saccharin sodium; sodium hydroxide; magnesium stearate; flavour - children: for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis, acute tonsilitis and impetigo. appropriate culture and sensitivity tests should be performed when necessary to determine an organism's susceptibility and thus treatment suitability. therapy may be initiated before results of these tests are known; once results become available, appropriate therapy should be continued.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - efavirenz, quantity: 600 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; sodium lauryl sulfate; hyprolose; lactose monohydrate; magnesium stearate; carnauba wax; titanium dioxide; hypromellose; iron oxide yellow; macrogol 400 - storcrin is indicated for use in combination with other antiviral agents for the treatment of hiv-1 infection in adults and children. (see clinical trials; use in children)

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: hypromellose; colloidal anhydrous silica; glucose; poloxamer; povidone; maize starch; purified talc; titanium dioxide; magnesium stearate; hyprolose; propylene glycol - for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms in; acute pharyngitis, tonsillitis, and sinusitis. acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia (including atypical pneumonia). skin and soft tissue infections and non-gonococcal urethritis

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 300 mg - tablet, film coated - excipient ingredients: purified talc; hyprolose; propylene glycol; maize starch; magnesium stearate; povidone; glucose; poloxamer; titanium dioxide; hypromellose; colloidal anhydrous silica - for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms: . acute pharyngitis, tonsillitis, sinusitis; . acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia; . skin and skin structure infections; . non-gonoccocal urethritis. appropriate culture and sensitivity tests should be performed when necessary to determine organisms' susceptibility and thus treatment suitability. therapy with rulide may be initiated before results of these tests are known; once results become available, appropriate therapy should be considered.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - roxithromycin, quantity: 150 mg - tablet, film coated - excipient ingredients: colloidal anhydrous silica; hyprolose; purified talc; magnesium stearate; glucose; titanium dioxide; maize starch; povidone; poloxamer; propylene glycol; hypromellose - adults: for the treatment of mild to moderately severe infections in adults caused by or likely to be caused by susceptible micro-organisms in: acute pharyngitis; tonsillitis and sinusitis. acute bronchitis and acute exacerbations of chronic bronchitis; community acquired pneumonia (including atypical pneumonia). skin and soft tissue infections and non-gonococcal urethritis children: for the treatment of the following mild to moderately severe infections in children caused by or likely to be caused by susceptible micro-organisms: acute pharyngitis; acute tonsillitis; impetigo.

オーストラリア - 英語 - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - emtricitabine, quantity: 200 mg; efavirenz, quantity: 600 mg; tenofovir disoproxil maleate, quantity: 300 mg - tablet, film coated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; sodium metabisulfite; hyprolose; colloidal anhydrous silica; croscarmellose sodium; magnesium stearate; ferric oxide; titanium dioxide; purified talc; iron oxide yellow; iron oxide red; polyvinyl alcohol; macrogol 3350 - tenofovir disoproxil/ emtricitabine/ efavirenz mylan 300/200/600 is indicated for the treatment of hiv infected adults over the age of 18 years.,this indication is based on analyses of plasma hiv-1 rna levels and cd4 cell counts in controlled studies of viread, emtriva and stocrin in treatment-na?ve and treatment experienced adults.